RxSight, Inc.(RXST)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,289 of 2,879 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
RXST Stock Analysis & AI Quality Score
AI stock analysis and institutional research for RxSight, Inc. (RXST), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RXST at 32.0/100 on a 32-signal composite quality model, placing it at rank #2,289 of 2,879 stocks — the bottom half of the AI-ranked universe. RXST scores in the top quartile across institutional flow (84.5), revenue growth (81.8). Areas of concern include profitability (11.9) and free cash flow (13.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 8.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), RxSight, Inc. reports quarterly revenue of $30.9M, net income of $-15.9M, free cash flow of $-11.7M. Top institutional holders of RXST by reported 13-F value include BlackRock,, MILLENNIUM MANAGEMENT, Artisan Partners Limited Partnership, based on the most recent SEC filings. RXST trades on the Nasdaq exchange and files with the SEC under CIK 1111485. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RXST daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for RxSight, Inc. directly from SEC EDGAR.
Revenue
Q1 2026
$30.9M
Net Income
Q1 2026
$-15.9M
Free Cash Flow
Q1 2026
$-11.7M
Get alerted when RXST's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for RxSight, Inc. including:
Top Institutional Holders of RXST
BlackRock, Inc.
$19.6M3,187,092 shMILLENNIUM MANAGEMENT LLC
$12.7M2,059,459 shArtisan Partners Limited Partnership
$12.7M2,058,684 shNOMURA HOLDINGS INC
$12.3M2,000,060 shNo Street GP LP
$12.3M2,000,000 shD. E. Shaw & Co., Inc.
$12.1M1,959,732 shVANGUARD CAPITAL MANAGEMENT LLC
$10.4M1,692,935 shTWO SIGMA INVESTMENTS, LP
$8.0M1,300,260 shBANK OF AMERICA CORP /DE/
$7.5M1,210,039 shHEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND
$7.0M1,131,400 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $19.6M | 3,187,092 |
| MILLENNIUM MANAGEMENT LLC | $12.7M | 2,059,459 |
| Artisan Partners Limited Partnership | $12.7M | 2,058,684 |
| NOMURA HOLDINGS INC | $12.3M | 2,000,060 |
| No Street GP LP | $12.3M | 2,000,000 |
| D. E. Shaw & Co., Inc. | $12.1M | 1,959,732 |
| VANGUARD CAPITAL MANAGEMENT LLC | $10.4M | 1,692,935 |
| TWO SIGMA INVESTMENTS, LP | $8.0M | 1,300,260 |
| BANK OF AMERICA CORP /DE/ | $7.5M | 1,210,039 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $7.0M | 1,131,400 |
More Healthcare Companies
View all Healthcare →Put RXST on your watchlist
Track score changes the day RxSight, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is RXST a good stock to buy?
13F Pro's AI-powered analysis of RxSight, Inc. (RXST) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RXST are available on the RXST stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own RXST?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RXST. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of RxSight, Inc.'s investment landscape.